What are the recommended treatment options for clear cell renal cell carcinoma, including surgical management for localized disease and systemic therapy for metastatic disease?

Clear Cell Renal Carcinoma Treatment

For localized clear cell RCC, perform partial or radical nephrectomy as the primary curative treatment; for metastatic disease, initiate combination immunotherapy plus VEGFR-TKI (nivolumab-cabozantinib or pembrolizumab-based combinations) as first-line therapy, reserving cytoreductive nephrectomy only for patients with durable responses to systemic therapy. 1, 2

Localized Disease (Non-Metastatic)

Surgical Management - Primary Treatment

For localized tumors, surgery remains the only potentially curative option:

• T1a/T1b tumors: Perform partial nephrectomy when technically feasible to preserve renal function
• Larger tumors or unfavorable anatomy: Radical nephrectomy is appropriate
• Biopsy: Obtain percutaneous renal mass biopsy before ablation procedures 1

Alternative Local Therapies for Surgical Non-Candidates

For patients medically unfit for surgery with cT1a/T1b tumors:

• Stereotactic body radiotherapy (SBRT/SABR) achieves 100% 1-year local control with grade 3-4 toxicity in only 0-9.1% of patients 1
• Thermal ablation is an alternative option

Critical caveat: Viable tumor cells often persist in post-SABR biopsies, though their clinical significance remains uncertain 1

Adjuvant Therapy for High-Risk Disease

Pembrolizumab is the only adjuvant therapy proven to improve both disease-free survival AND overall survival in high-risk localized ccRCC (HR 0.62 for OS at 57.2-month follow-up) 1

• Previous TKI monotherapy trials (including sunitinib in S-TRAC) showed no OS benefit despite DFS improvements, with high grade 3-4 toxicity rates 1
• Neoadjuvant therapy remains investigational with no proven OS benefit; reserve for clinical trials only 1

Metastatic Disease

First-Line Systemic Therapy - The New Standard

Combination immunotherapy plus VEGFR-TKI is now standard of care, having replaced TKI monotherapy:

Preferred regimens (all superior to sunitinib monotherapy):

• Nivolumab plus cabozantinib: Final 5.6-year follow-up shows median OS 46.5 months versus 35.5 months with sunitinib (HR 0.79), with 60-month OS rates of 40.9% versus 35.4% 3
• Pembrolizumab-based combinations with VEGFR-TKIs 2

These combinations demonstrate:

• Significantly improved progression-free survival (median PFS 16.4 vs 8.3 months for nivo-cabo) 3
• Higher objective response rates (55.7% vs 27.4% for nivo-cabo) 3
• Complete response rates of 13.9% versus 4.6% 3

Important toxicity consideration: Grade 3-4 treatment-related adverse events occur in 67.8% with nivolumab-cabozantinib versus 55.0% with sunitinib, but no new deaths from toxicity occurred in long-term follow-up 3

Role of Cytoreductive Nephrectomy - Paradigm Shift

The era of upfront cytoreductive nephrectomy is over. Start with systemic therapy first 1:

• CARMENA trial demonstrated sunitinib alone was non-inferior to immediate CN followed by sunitinib (median OS 18.4 vs 13.9 months) 1
• SURTIME trial showed dramatic OS benefit favoring deferred CN (32.4 vs 15.0 months with immediate CN) 1
• Current recommendation: Begin immediate systemic treatment; offer deferred CN only to patients achieving durable responses 1

Rationale: Since pivotal ICI trials included patients with primary tumors in place, and ICI-based therapy has replaced TKIs as first-line standard, immediate systemic treatment takes priority until higher-level evidence emerges 1

Second-Line Therapy

After progression on first-line ICI-VEGFR combination:

Cabozantinib monotherapy is the preferred second-line option with impressive results:

• ORR 40.9% and median PFS 10.8 months in CONTACT-03 (100% had prior ICI) 2
• ORR 28% and median PFS 9.3 months in CANTATA (62% had prior ICI) 2

Alternative: Belzutifan (HIF2α inhibitor) versus everolimus, though with weaker recommendation than cabozantinib 2

Third-Line and Beyond

Belzutifan is superior to everolimus in heavily pretreated patients (HR 0.75 for PFS):

• Higher ORR (23% vs 4%) 2
• Better toxicity profile and quality of life 2
• Interim OS showed no benefit yet (HR 0.88) 2

Alternative approach: Sequential VEGFR-targeted therapy remains viable 2

Avoid: ICI rechallenge is unproven and not standard 2

Local Therapy for Oligometastatic Disease

For patients with oligometastases or oligoprogression:

• Metastasectomy can be considered for complete surgical excision
• Stereotactic radiotherapy for brain and possibly bone metastases 1
• Evidence caveat: Systematic reviews show only retrospective non-randomized studies with high bias risk 1

Common Pitfalls to Avoid

1. Don't perform upfront cytoreductive nephrectomy in intermediate/poor-risk mRCC—start systemic therapy first
2. Don't use adjuvant TKI monotherapy (like sunitinib) despite DFS benefit—only pembrolizumab has proven OS benefit
3. Don't use neoadjuvant therapy outside clinical trials—no OS benefit demonstrated
4. Don't rechallenge with ICIs in later lines—this is unproven
5. Don't delay systemic therapy to pursue CN in metastatic disease—the CARMENA trial changed this paradigm